Background and Aims: The antigastric antibodies present in Helicobacter pylori infection act as a marker for an ongoing antigastric autoimmune process in the gastric mucosa, which can already be diagnosed in the non-atrophic stage. In a retrospective, uncontrolled study, therefore, we investigated the question as to whether this type of gastritis can be healed by the eradication of H. pylori. Patients and Methods: In 80 patients with an active, not yet atrophic autoimmune gastritis, we analysed a maximum of four investigations per patient over a period of up to 39.5 months. The following parameters were graded in the antral and corpus mucosa prior to and after H. pylori eradication treatment: grade and activity of the gastritis, H. pylori colonization, atrophy, parietal cell hypertrophy, and incidence of intestinal metaplasia. In addition, the typical parameters for this type of gastritis, such as grade of the periglandular lymphocytic infiltration, grade of glandular destruction and incidence of nodular ECL cell proliferates in the corpus mucosa were determined. Results: In 64 patients (80%), H. pylori eradication treatment was followed by healing of the active autoimmune corpus gastritis, that is, the activity of the gastritis disappeared, and lymphocytic infiltration of the glands, glandular destruction and parietal cell hypertrophy was found to be significantly reduced. Conclusions: Our uncontrolled, retrospective study confirms the existence of an active, not yet atrophic autoimmune gastritis as a sequela of H. pylori infection.

Journal Section:
Original Paper: Gastric Disorders
Keywords:
Autoimmune gastritis, Helicobacter pylori
1.
Rappel S, Altendorf-Hofmann A, Stolte M: Prognosis of gastric carcinoid tumors. Digestion 1994;56:455–462.
2.
Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study. Gastroenterology 1993;104:994–1006.
[PubMed]
3.
Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E: Gastric carcinoids and neuroendocrine carcinomas: Pathogenesis, pathology and behavior. World J Surg 1996;20:168–172.
[PubMed]
https://doi.org/10.1007/s002689900026
4.
Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G: Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 1994;55(suppl 3):11–23.
5.
Varis K: Surveillance of pernicious anemia; in Sherlock P, Morson BC, Barbara L, Versonesi U (eds): Precancerous Lesions of the Gastrointestinal Tract. New York, Raven Press, 1983, pp 189–194.
6.
Strickland RG, Mackay IR: A reappraisal of the nature and significance of chronic atrophic gastritis. Dig Dis 1973;18:426–440.
7.
Stolte M, Baumann H, Bethke B, Lauer E, Ritter M: Active autoimmune gastritis without total atrophy of the glands. Z Gastroenterol 1992;30:729–730.
[PubMed]
8.
Negrini R, Savio A, Poiesi C et al: Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 1996;111:655–665.
[PubMed]
9.
Faller G, Steininger H, Eck M, Hensen J, Han EG, Kirchner T: Antigastric autoantibodies in Helicobacter pylori gastritis: Prevalence, in-situ binding sites and clues for clinical relevances. Virchows Arch 1996;427:483–486.
[PubMed]
10.
Faller G, Steininger H, Kränzlein J, Maul H, Kerkau T, Hensen J, Hahn EG, Kirchner T: Antigastric autoantibodies in Helicobacter pylori infection: Implications of histological and clinical parameters of gastritis. Gut 1997;41:619–623.
[PubMed]
11.
Appelmelk BJ, Faller G, Claeys D, Kirchner T, Vandenbroucke-Grauls CMJE: Bugs on trial: The cause of Helicobacter pylori and autoimmunity. Immunol Today 1998;19:296–299.
[PubMed]
https://doi.org/10.1016/S0167-5699(98)01281-X
12.
Burmann P, Mardh S, Nordberg L, Karlsson FA: Parietal cell antibodies in pernicious anemia inhibit H+,K+-adenosine triphosphate, the proton pump of the stomach. Gastroenterology 1989;96:1434–1438.
[PubMed]
13.
Claeys D, Faller G, Appelmelk, BJ, Negrini R, Kirchner T: The H+,K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology 1998;115:340–347.
[PubMed]
14.
Faller G, Steininger H, Appelmelk B, Kirchner T: Evidence of novel pathways for the formation of antigastric autoantibodies in Helicobacter pylori gastritis. J Clin Pathol 1998;51:244–245.
[PubMed]
15.
Stolte M, Meier E, Meining A: Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. Z Gastroenterol 1998;36:641–643.
[PubMed]
16.
Stolte M, Meining A, Koop H, Seifert E: Eradication of Helicobacter pylori heals atrophic corpus gastritis caused by long-term treatment with omeprazole. Virchows Arch 1999;434:91–94.
[PubMed]
https://doi.org/10.1007/s004280050310
17.
Oberhuber G, Wündisch T, Rappel S, Stolte M: Significant improvement of atrophy after eradication therapy in atrophic body gastritis. Pathol Res Pract 1998;194:609–613.
[PubMed]
18.
Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. Am J Surg Pathol 1996;20:1161–1181.
[PubMed]
https://doi.org/10.1097/00000478-199610000-00001
19.
Karnes WE Jr, Samloff IM, Siurala M, Kekki M, Sipponen P, Kim SW, Walsh JH: Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 1991;101:167–174.
[PubMed]
20.
Valle J, Kekki M, Sipponen P, Ihamaki T, Siurlala M: Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 1996;31:546–550.
[PubMed]
21.
Flejou JF, Bahame P, Smith AC, Stockbrügger RH, Rode J, Price AB: Pernicious anemia and Campylobacter-like organisms: Is the gastric antrum resistant to colonisation? Gut 1989;30:60–64.
[PubMed]
22.
Vogt K, Hahn H: Influence of omeprazole on urease activity of Helicobacter pylori in vitro. Zentralbl Bakt 1993;280:272–280.
23.
Verdu EF, Viani F, Armstrong D, Fraser R, Siegrist HH, Pignatelli B, Idstrom JP, Cederberg C, Blum AL, Fried M: Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut 1994;35:455–460.
[PubMed]
24.
Sharma BK, Santana IA, Wood EC, Walt RP, Pereira M, Noone P, Smith PL, Walters CL, Pounder RE: Intragastric bacterial activity and nitrosation before, during and after treatment with omeprazole. Br Med J 1984;289:717–720.
25.
Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G, Borsch G, Blum AL: Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743–748.
[PubMed]
26.
Meyer-Rosenberg K, Scott DR, Rex D, Melchers K, Sachs G: The effect of environmental pH on proton motive force of Helicobacter pylori. Gastroenterology 1996;111:886–890.
[PubMed]
27.
Stolte M, Bethke B: Elimination of Helicobacter pylori under treatment with omeprazole. Z Gastroenterol 1990;28:271–274.
[PubMed]
28.
Logan RPH, Walter MM, Misiewicz JJ, Gummet PA, Karim QN, Baron JH: Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995;36:12.
[PubMed]
29.
Stolte M, Meining A, Schmitz JM, Alexandriis T, Seifert E: Changes in Helicobacter pylori-induced gastritis in the antrum and corpus under 12 months of treatment with omeprazole and lanzoprazole. Aliment Pharmacol Ther 1998;12:247–253.
[PubMed]
30.
Eissele R, Brunner G, Simon B, Solcia E, Arnold R: Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk for argyrophil cell hyperplasia. Gastroenterology 1997;112:707–717.
[PubMed]
31.
Oberhuber G, Puspok A, Dejaco C, Hammer J, Zauner C, Pfeffel F, Fiedler R, Potzi R, Allerberger F, Wrba F: Minimal chronic inactive gastritis: Indicator of pre-existing Helicobacter pylori gastritis? Pathol Res Pract 1996;192:1016–1021.
[PubMed]
32.
Solcia E, Villiani L, Fiocca R, Luinetti O, Boldorini R, Trespi E, Perego M, Alvisi C, Lazzaroni M, Bianci PB: Effect of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 1994;29(suppl 201):28–34.
33.
Stolte M, Bethke B, Rühl G, Ritter M: Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol 1992;30:134–138.
[PubMed]
34.
El-Omar EE, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, Williams C, Ardill JES, McColl KEL: Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15–24.
[PubMed]
35.
Van den Hulst RW, van der Ende A, Dekker FW, Ten Kate FJ, Weel JF, Kellern JJ, Kruizinga SP, Dankert J, Tytgat GN: Effect of Helicobacter pylori eradication on gastritis in relation to CagA: A prospective 1-year follow-up study. Gastroenterology 1997;113:25–30.
[PubMed]
36.
Griffiths AE, Thursz MR, Walker MM: Do intestinal metaplasia and gastric atrophy reverse after Helicobacter pylori eradication? Gut 1997;41(suppl 1):A48–A49.
37.
Tucci A, Biasco G, Paparo GF: Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis. N Engl J Med 1997;336:957–958.
[PubMed]
https://doi.org/10.1056/NEJM199703273361313
38.
Annibale B, Marignani M, Azzoni C et al: Atrophic body gastritis: Distinct features associated with Helicobacter pylori infection. Helicobacter 1997;2:57–64.
[PubMed]
© 2001 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2001
You do not currently have access to this content.